Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205777 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,609
- Enrollment target
NCT00205777: Completed Phase 3 study, sponsored by Pfizer.
NCT00205777 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 7,609 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (886% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00205777, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,609 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.
Primary Outcome
New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification fact
Interventions
- OTHER Placebo
- DRUG Bazedoxifene Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,609 participants |
| Start Date | 2001-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
What the finished NCT00205777 record still lists
NCT00205777 is an interventional study that assigns participants to a tested intervention. Its 7,609 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (886% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00205777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00205777 about?
NCT00205777 is a clinical study titled "Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women". The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.
What is the current status of trial NCT00205777?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,609 participants. The study started on 2001-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00205777?
The interventions under investigation include: Placebo (OTHER), Bazedoxifene Acetate (DRUG).
Who is sponsoring clinical trial NCT00205777?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00205777's enrollment target sits among peer trials
7,609 33rd of 2000 higher than 1,968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03848312 · 7,600 participants · Phase 3
Preventing Alzheimer's With Cognitive Training
- NCT06560398 · 7,649 participants · NA
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia